lifestyle.gooddecisions.com

Author: TheRas, Inc. (d/b/a BBOT)

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

April 20, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 13, 2026
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

March 18, 2026
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

March 6, 2026
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

March 5, 2026
BBOT to Participate in Upcoming Investor Healthcare Conferences

February 14, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 13, 2026